Project Grant R44CA291336
Award Date
9/23/24
Completion Date
8/31/26
Dollars Obligated
$1.1M
Federal Agency
National Cancer Institute
Awardee
Teal Health Inc. (TSDUXS8SK2L3)
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94129, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $962,560 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Basic Health International Inc., a non-profit organization based in Pittsburgh, Pennsylvania. The purpose of this 5-year grant (award date: September 18, 2024) is to modify and clinically validate the IRISTM device, a handheld thermal ablation device and digital colposcope designed for cervical cancer screening and treatment in low- and middle-income countries...
The National Cancer Institute awarded a $957,152 Cooperative Agreement under the Cancer Detection and Diagnosis Research (CFDA 93.394) program to GE Medical Systems Information Technologies, Inc. to develop and deploy an affordable automated point-of-care telecytology platform for oral cancer screening in India. The project aims to reliably establish a diagnosis of oral cancer in the community setting and create an immediate referral care pathway. Key components include a portable system for...
The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $1,172,978 Phase II Small Business Innovation Research (SBIR) grant to Ananya Health Inc. to develop a portable, battery-powered, closed-loop cryotherapy system for the treatment of cervical precancerous lesions in low- and middle-income countries (LMICs). The key objectives of this 2-year project are to: 1) finalize the system design and verify it meets all requirements...
This Cooperative Agreement award from the National Cancer Institute (NCI), under the federal grant program "Cancer Detection and Diagnosis Research" (CFDA 93.394), aims to develop a point-of-care HPV DNA test for cervical cancer screening in Mozambique. The total award is $585,943, with a performance period from September 1, 2024 to August 31, 2029. The key objectives are to: 1) Adapt existing extraction-free, multiplexed, isothermal nucleic acid amplification assays to detect 8...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $549,536 to the Trustees of Dartmouth College to develop an innovative 3D wearable near-infrared (NIR) spectral tomography system. The objective is to create a clinical platform capable of early prediction of residual cancer burden in breast cancer patients undergoing neoadjuvant chemotherapy. The proposed technological innovations focus...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $554,188 to The Trustees of the University of Pennsylvania to develop novel silver telluride nanoparticle contrast agents for improved breast cancer screening via dual-energy mammography. The key objectives are to: Adapt the nanoparticle synthesis process for microfluidic chip manufacturing to enable rapid prototyping and scale-up. Characterize the microfluidic-produced...
The National Science Foundation awarded a $275,000 Project Grant to Oraliva, Inc. under the Technology, Innovation, and Partnerships program to develop a portable, programmable single cell cytology platform for the early detection of epithelial cancers. The platform will combine microfluidics and artificial intelligence to classify potentially cancerous tissue in near real-time through multiparameter single-cell analysis and automated evaluation. The objectives are to link different clinical...
This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $670,534 to Northwestern University to develop an optical hyperspectral nanoscale chromatin analysis technology for colorectal cancer risk-stratification. The goal is to create a highly accurate, low-cost screening test that can be administered in primary care settings to identify patients who should undergo colonoscopy, with a target of 99.5% negative predictive...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $367,472 to support the development of Gynion, LLC's ClaraBlex gel for the ablative treatment of cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection. The ClaraBlex gel, formulated with trichloroacetic acid, is designed to provide a simple, effective, and affordable point-of-care treatment that can be readily...